Ligand validation:3U75

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 3U75 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
3U75_NAG_C_1394	55%	32%	0.133	0.901	0.59	2.08	-	5	0	0	100%	0.9333
3U75_NAG_C_1219	49%	34%	0.145	0.89	0.97	1.63	-	4	0	0	100%	0.9333
3U75_NAG_D_1219	45%	45%	0.156	0.887	0.74	1.36	-	3	0	0	100%	0.9333
3U75_NAG_A_1219	41%	54%	0.168	0.884	0.54	1.22	-	3	0	0	100%	0.9333
3U75_NAG_B_1219	41%	45%	0.162	0.875	0.76	1.35	-	3	0	0	100%	0.9333
3U75_NAG_B_1394	35%	42%	0.158	0.845	0.53	1.7	-	2	1	0	100%	0.9333
3U75_NAG_D_1394	13%	18%	0.263	0.799	0.94	2.57	-	7	0	0	100%	0.9333
6S2B_NAG_B_601	86%	51%	0.083	0.952	0.55	1.32	-	3	0	0	100%	0.9333
6S1T_NAG_B_602	78%	66%	0.098	0.94	0.48	0.83	-	1	0	0	100%	0.9333
3U14_NAG_B_1219	54%	8%	0.151	0.914	1.74	2.78	2	6	0	0	100%	0.9333
3KF3_NAG_A_3001	47%	56%	0.128	0.865	0.57	1.11	-	1	0	0	100%	0.9333
3KF5_NAG_A_4001	44%	43%	0.185	0.913	0.45	1.71	-	4	1	0	100%	0.9333
1OC7_NAG_A_500	100%	60%	0.04	0.991	0.61	0.9	-	1	0	0	100%	0.9333
1OC6_NAG_A_500	100%	67%	0.041	0.988	0.46	0.8	-	1	0	0	100%	0.9333
1UWC_NAG_A_262	100%	54%	0.046	0.99	0.83	0.93	-	-	0	0	100%	0.9333
6ZE6_NAG_B_703	100%	52%	0.044	0.984	0.78	1.07	-	2	0	0	100%	0.8667
6ZE2_NAG_B_704	99%	56%	0.042	0.979	0.73	0.95	-	1	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.